Tag: Patients
Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Smal

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Smal

DARMSTADT, Germany and NEW YORK, February 15, 2018 /PRNewswire/ -- Not intended for UK-based media Merck and Pfizer Inc. today announced results from the Phase III JAVELIN ...

Lees verder
Takeda and Cognition Kit Present Results from Digital Wearable Technology Study in patients with Major Depressive Disorder (MDD)

Takeda and Cognition Kit Present Results from Digital Wearable Technology Study in patients with Major Depressive Disorder (MDD)

CAMBRIDGE, England, and DEERFIELD, Illinois, Nov. 17, 2017 /PRNewswire/ -- Takeda and Cognition Kit today announced that the companies will present results from MDD-5003, a ...

Lees verder
Galderma: 'Clear' (IGA 0) Rosacea Patients Experience a Delayed Time to Relapse

Galderma: 'Clear' (IGA 0) Rosacea Patients Experience a Delayed Time to Relapse

LAUSANNE, Switzerland, September 16, 2017 /PRNewswire/ -- Today, the results of a pooled analysis of four Galderma-sponsored studies evaluating the use of topical therapies ...

Lees verder
Combination Data for Lenvatinib and Pembrolizumab Demonstrate Notable Response Rates for Patients with Advanced Renal Cell Carcinoma

Combination Data for Lenvatinib and Pembrolizumab Demonstrate Notable Response Rates for Patients with Advanced Renal Cell Carcinoma

HATFIELD, England, September 9, 2017 /PRNewswire/ -- FOR EMEA MEDICAL MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTS  - Updated results of advanced RCC cohort from ...

Lees verder
New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk S

New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk S

MUNICH, August 29, 2017 /PRNewswire/ -- - Sub-analysis highlights the protective effect of edoxaban against stroke or systemic embolic events (SEEs) and its ...

Lees verder
German Federal Joint Committee (G-BA) Confirms Evidence for Additional Benefit for CINQAERO® (reslizumab) in Severe Asthma Patients with an Eleva

German Federal Joint Committee (G-BA) Confirms Evidence for Additional Benefit for CINQAERO® (reslizumab) in Severe Asthma Patients with an Eleva

AMSTERDAM, July 6, 2017 /PRNewswire/ -- Positive Assessment in Germany Brings More Patients Closer to Gaining Access to CINQAERO(R)   Teva Pharmaceuticals Europe BV, today ...

Lees verder
Data Provide Additional Insight Into the Mode of Action of MAVENCLAD(TM) (Cladribine Tablets) in Patients With Relapsing MS

Data Provide Additional Insight Into the Mode of Action of MAVENCLAD(TM) (Cladribine Tablets) in Patients With Relapsing MS

DARMSTADT, Germany, June 26, 2017 /PRNewswire/ -- - Data suggest that MAVENCLAD(TM) (Cladribine Tablets) selectively and discontinuously reduces B and T ...

Lees verder
European Hematology Association: Global Trial of the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-

European Hematology Association: Global Trial of the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-

MADRID, June 24, 2017 /PRNewswire/ -- CTL019 consists of genetically engineered autologous T cells expressing a chimeric antigen receptor (CAR). Results from a prior ...

Lees verder
Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017

Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017

DARMSTADT, Germany, June 24, 2017 /PRNewswire/ -- - New data builds on company's longstanding commitment to MS  Merck, a leading science and technology company, ...

Lees verder
European Hematology Association: Bleeding or Clotting in Elderly Patients with Cancer-Associated Venous Thromboembolism: Which is Worse?

European Hematology Association: Bleeding or Clotting in Elderly Patients with Cancer-Associated Venous Thromboembolism: Which is Worse?

MADRID, June 24, 2017 /PRNewswire/ -- The risk of blood clots in the veins of the legs or the lungs, known as venous thrombosis (VTE) is higher in cancer patients, and so is ...

Lees verder
BizPress.nl